Trial Profile
A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 14 Apr 2023 Status changed from active, no longer recruiting to completed.
- 22 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2022 The trial has been discontinued in Bulgaria, according to Eudra record.